MX421668B - Derivado de péptido-1 (glp-1) similar al glucagón acilado - Google Patents

Derivado de péptido-1 (glp-1) similar al glucagón acilado

Info

Publication number
MX421668B
MX421668B MX2020011007A MX2020011007A MX421668B MX 421668 B MX421668 B MX 421668B MX 2020011007 A MX2020011007 A MX 2020011007A MX 2020011007 A MX2020011007 A MX 2020011007A MX 421668 B MX421668 B MX 421668B
Authority
MX
Mexico
Prior art keywords
glucagon
derivative
glp
acylated
medicament
Prior art date
Application number
MX2020011007A
Other languages
English (en)
Other versions
MX2020011007A (es
Inventor
Feng Li
Hai Pan
Jianhui Deng
Jing Feng
Rui Song
Wanjun Guo
Zhaosheng Lin
Zheng Xu
Original Assignee
Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciwind Biosciences Co Ltd filed Critical Sciwind Biosciences Co Ltd
Publication of MX2020011007A publication Critical patent/MX2020011007A/es
Publication of MX421668B publication Critical patent/MX421668B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un análogo de polipéptido GLP-1 (7-37), un derivado modificado con ácido graso del análogo y un medicamento que comprende el derivado; además, también se proporciona un método de preparación del derivado y el uso del mismo en la preparación de un medicamento.
MX2020011007A 2018-04-19 2019-04-19 Derivado de péptido-1 (glp-1) similar al glucagón acilado MX421668B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/083789 WO2019200594A1 (zh) 2018-04-19 2018-04-19 酰化的glp-1衍生物
PCT/CN2019/083383 WO2019201328A1 (zh) 2018-04-19 2019-04-19 酰化的glp-1衍生物

Publications (2)

Publication Number Publication Date
MX2020011007A MX2020011007A (es) 2021-01-20
MX421668B true MX421668B (es) 2025-03-14

Family

ID=68239398

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011007A MX421668B (es) 2018-04-19 2019-04-19 Derivado de péptido-1 (glp-1) similar al glucagón acilado
MX2025001943A MX2025001943A (es) 2018-04-19 2020-10-16 Derivado de peptido-1 (glp-1) similar al glucagon acilado

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025001943A MX2025001943A (es) 2018-04-19 2020-10-16 Derivado de peptido-1 (glp-1) similar al glucagon acilado

Country Status (9)

Country Link
US (2) US11612640B2 (es)
EP (1) EP3783014A4 (es)
JP (2) JP7164247B2 (es)
KR (2) KR102464605B1 (es)
AU (2) AU2019256245B2 (es)
BR (1) BR112020021245A8 (es)
CA (2) CA3135910C (es)
MX (2) MX421668B (es)
WO (2) WO2019200594A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
EP4159712B1 (en) 2020-05-29 2025-03-19 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
CN113025675B (zh) * 2021-05-21 2021-08-20 凯莱英医药集团（天津）股份有限公司 多肽的制备方法
WO2023151594A1 (en) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法
CN117467649A (zh) * 2022-10-31 2024-01-30 杭州先为达生物科技股份有限公司 高特异性肠激酶酶切方法及乙醇在提高肠激酶酶切特异性中的用途
CN117247422A (zh) * 2022-12-06 2023-12-19 杭州先为达生物科技股份有限公司 一种多肽衍生物及其制备方法
CN121358486A (zh) 2023-06-30 2026-01-16 杭州先为达生物科技股份有限公司 具有提高药物口服生物利用度的组合物及其方法
WO2026008836A1 (en) 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US692464A (en) 1901-05-04 1902-02-04 Daniel Mackenzie Combined baby carriage and sleigh.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
KR20020002480A (ko) * 1999-03-17 2002-01-09 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 펩티드의 아실화법 및 신규한 아실화제
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
MXPA02007231A (es) * 2000-01-27 2002-12-09 Lilly Co Eli Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
WO2005072045A2 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
EP1765873A4 (en) * 2004-07-01 2009-07-01 Waratah Pharmaceuticals Inc COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101342365A (zh) * 2008-08-28 2009-01-14 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物的用途
CN101367873B (zh) 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
WO2011156407A2 (en) 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancre-atitis
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
EP3016975B1 (en) 2013-07-04 2019-01-16 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
ES2741507T3 (es) * 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物

Also Published As

Publication number Publication date
AU2021204749A1 (en) 2021-07-29
KR20210005093A (ko) 2021-01-13
AU2019256245A1 (en) 2020-11-19
US12508300B2 (en) 2025-12-30
CA3202015A1 (en) 2019-10-24
JP7499305B2 (ja) 2024-06-13
EP3783014A9 (en) 2021-05-19
EP3783014A1 (en) 2021-02-24
CA3135910A1 (en) 2019-10-24
JP2022191398A (ja) 2022-12-27
JP7164247B2 (ja) 2022-11-01
KR102653113B1 (ko) 2024-04-02
CA3135910C (en) 2023-08-22
US20230330189A1 (en) 2023-10-19
AU2021204749B2 (en) 2022-03-31
WO2019200594A1 (zh) 2019-10-24
US11612640B2 (en) 2023-03-28
US20210393744A1 (en) 2021-12-23
KR102464605B1 (ko) 2022-11-10
AU2019256245B2 (en) 2021-08-05
WO2019201328A1 (zh) 2019-10-24
JP2021522318A (ja) 2021-08-30
BR112020021245A8 (pt) 2022-05-10
MX2020011007A (es) 2021-01-20
KR20220035996A (ko) 2022-03-22
BR112020021245A2 (pt) 2021-02-02
EP3783014A4 (en) 2021-07-07
MX2025001943A (es) 2025-04-02

Similar Documents

Publication Publication Date Title
MX421668B (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado
CL2020002574A1 (es) Análogos novedosos de glp-1
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
CL2020001899A1 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante.
CO2020002647A2 (es) Composiciones de glp-1 y sus usos
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
DOP2024000040A (es) Vacunas para vhb y métodos de tratamiento de vhb
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
TWD208140S (zh) 手錶
ECSP17038136A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
CL2023003091A1 (es) Compuestos de péptidos similares al glucagón
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
MX2021015840A (es) Polipeptido modificado de meso-diaminopimelato deshidrogenasa y procedimiento de produccion de l-treonina mediante el uso del mismo.
UY35794A (es) Glicoproteínas recombinantes y usos de las mismas.
CL2022001393A1 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el